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Abstract
Background: A substantial number of microRNAs (miRNAs) is subject to epigenetic silencing in cancer. Although 
epigenetic silencing of tumour suppressor genes is an important feature of cervical cancer, little is known about 
epigenetic silencing of miRNAs. Since DNA methylation-based silencing of hsa-miR-124 occurs in various human 
cancers, we studied the frequency and functional effects of hsa-miR-124 methylation in cervical carcinogenesis.
Results: Quantitative MSP analysis of all 3 loci encoding the mature hsa-miR-124 (hsa-miR-124-1/-2/-3) showed 
methylation in cervical cancer cell lines SiHa, CaSki and HeLa as well as in late passages of human papillomavirus (HPV) 
type 16 or 18 immortalised keratinocytes. Treatment of SiHa cells with a demethylating agent reduced hsa-miR-124 
methylation levels and induced hsa-miR-124 expression. In HPV-immortalised keratinocytes increased methylation 
levels were related to reduced hsa-miR-124 expression and higher mRNA expression of IGFBP7, a potential hsa-miR-124 
target gene. Ectopic hsa-miR-124 expression in SiHa and CaSki cells decreased proliferation rates and migratory 
capacity. Combined hsa-miR-124-1 and/or hsa-miR-124-2 methylation analysis of 139 cervical tissue specimens 
showed an increasing methylation frequency from 0% in normal tissues up to 93% in cervical carcinomas. Increased 
methylation levels of hsa-miR-124-1 and hsa-miR-124-2 were significantly correlated with reduced hsa-miR-124 
expression in cervical tissue specimens. Combined hsa-miR-124-1 and/or hsa-miR-124-2 methylation analysis of 43 
cervical scrapes of high-risk HPV positive women was predictive of underlying high-grade lesions.
Conclusions: DNA methylation-based silencing of hsa-miR-124 is functionally involved in cervical carcinogenesis and 
may provide a valuable marker for improved detection of cervical cancer and its high-grade precursor lesions.
Background
Cervical cancer is the second most common cancer in
women worldwide and is caused by a persistent infection
with high-risk types of the human papillomavirus
(hrHPV) [1-3]. The development of cervical squamous
cell carcinomas (SCCs, representing about 80% of cases)
occurs via well-recognisable premalignant precursor
lesions (cervical intraepithelial neoplasia (CIN), graded
1-3), whereas less is known about the different precursor
stages preceding cervical adenocarcinomas (AdCAs,
accounting for 10-20% of cases).
Even taking the promising results of recently intro-
duced prophylactic HPV vaccines into account, cervical
screening will remain necessary in the foreseeable future
[4-7]. Recent studies have shown that the sensitivity of
hrHPV testing is superior to that of cytology as a screen-
ing tool [8-10]. However, hrHPV testing also results in
the identification of a considerable number of hrHPV-
positive women without (pre)cancerous lesions, necessi-
tating the development of proper triage tests for hrHPV-
positive women. Assays detecting (epi)genetic changes
that besides hrHPV are crucial for malignant progression
will likely contribute to the discrimination of hrHPV pos-
itive women with cervical (pre)cancer.
DNA methylation-mediated silencing of an increasing
number of protein-coding tumour suppressor genes is
* Correspondence: r.steenbergen@vumc.nl
1 Department of Pathology, VU University Medical Center, Amsterdam, The 
Netherlands
Full list of author information is available at the end of the article© 2010 Wilting et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Wilting et al. Molecular Cancer 2010, 9:167
http://www.molecular-cancer.com/content/9/1/167
Page 2 of 14known to be involved in cervical cancer. Therefore, the
present study aimed to investigate whether epigenetic
changes relevant in hrHPV-mediated cervical carcino-
genesis may affect the expression microRNAs (miRNAs)
as well [11-16]. miRNAs, ~23 nucleotide long, non-cod-
ing RNAs, regulate expression of protein-coding genes at
the posttranscriptional level by sequence specific base
pairing in the 3' untranslated region (UTR) of the target
mRNAs. Recent proteomic studies have shown that a sin-
gle miRNA can regulate expression of hundreds of targets
[17,18]. The potential importance of miRNAs in cervical
carcinogenesis in general, is underlined by a number of
studies. miRNA loci are significantly associated with
fragile sites, which are known insertion sites of HPV in
cervical cancers. In addition, even though no HPV-
encoded miRNAs have been identified so far, HPV-
encoded genes were shown to influence the miRNA
expression of its host cell [19,20]. Altered miRNA expres-
sion was found in cervical cancer cell lines and/or cervi-
cal carcinomas compared to normal controls and a
number of these differentially expressed miRNAs were
shown to influence proliferation rates of cervical cancer
cell lines SiHa or HeLa [20-24].
Interestingly, similar to protein-coding tumour sup-
pressor genes, expression of a substantial number of miR-
NAs was shown to be under epigenetic regulation [25-
31]. A well-known epigenetically silenced miRNA in
human carcinogenesis is hsa-miR-124. DNA methylation
of hsa-miR-124 was first shown by Lujambio et al in
colon, breast and lung cancer, as well as in leukaemia and
lymphoma [29]. Subsequent studies confirmed frequent
hsa-miR-124 methylation in leukaemia affecting clinical
outcome and additionally showed frequent hsa-miR-124
methylation in gastric cancer and hepatocellular carci-
noma [25,26,30,32]. At present, no studies have been per-
formed to investigate the role of epigenetic silencing of
miRNAs in cervical cancer.
In this study we evaluated the potential role of DNA
methylation-based silencing of hsa-miR-124 during cer-
vical carcinogenesis. The mature hsa-miR-124 sequence
is processed from 3 separate premature sequences,
located at chromosomes 8p23.1 (miR-124-1), 8q12.3
(miR-124-2) and 20q13.33 (miR-124-3), all of which con-
tain CpG islands in their promoter regions. We investi-
gated the methylation status of all 3 genomic loci
encoding the mature hsa-miR-124 in cervical cancer cell
lines, a longitudinal in vitro model system of hrHPV-
induced carcinogenesis [33], cervical tissue specimens (n
= 139), and hrHPV-positive cervical scrapes (n = 43) of
women with and without a CIN3 diagnosis in follow-up.
In addition, effects of (ectopic) hsa-miR-124 expression
on cellular proliferation, migration and mRNA expres-
sion of IGFBP7, a potential target gene, were studied.
Materials and methods
Cell lines and cell culture
Establishment and culture of the HPV16 (FK16A/FK16B)
and HPV18 (FK18A/FK18B) immortalised cell lines have
been described previously [33]. Primary human keratino-
cytes, referred to as EK cells, were isolated from foreskin
and cultured as described previously [33]. The human
cervical carcinoma cell lines SiHa, CaSki and HeLa were
obtained from the American Type Culture Collection
(Manassas, VA, USA). SiHa cells were treated with 5000
nM 5-aza-2'-deoxycytidine (DAC, Sigma Chemical Co.,
St. Louis, MO, USA) dissolved in PBS to analyse the effect
of global methylation inhibition on hsa-miR-124 expres-
sion.
Clinical tissue specimens
We used frozen specimens of normal cervix (n = 5),
CIN2/3 (n = 7), SCC (n = 9) and AdCA (n = 5) as well as
formalin-fixed, paraffin-embedded (FFPE) biopsy speci-
mens of normal cervix (n = 18), CIN1 (n = 36), CIN3 (n =
41), SCC (n = 29) and AdCA (n = 15). All specimens were
collected during the course of routine clinical practice
and stored at the Department of Pathology at the VU
University Medical Center (Amsterdam, the Nether-
lands). Normal specimens were obtained from non-can-
cer patients undergoing hysterectomy. The mean age of
all women included in this study was 40.3 years (range
18-79). Per histological subgroup the women had the fol-
lowing mean ages: 49.1 years (range 34-70) in the normal
group; 35.9 (range 22-52) years in the CIN1 group; 35.9
years (range 27-74) in the CIN3 group; 53.0 years (range
35-61) in the SCC group; 45.6 years (range 28-79) in the
AdCA group. The mean age in any of the groups of
women with cervical (pre)malignant disease was not sig-
nificantly higher than that of the women with normal his-
tology.
Cervical scrapings were obtained from the population-
based cervical screening trial POBASCAM, registered as
an International Standard Randomized Controlled Trial
under number ISRCTN20781131 [8,34]. For this study,
we selected 22 cervical scrapes from hrHPV-positive
women who had normal cytology without evidence of
CIN disease up to the next screening round (i.e. 5 years)
and 21 scrapings classified as severe dyskaryosis or worse
from hrHPV-positive women who had a CIN3 diagnosis
within 18 months of follow-up. The mean age of the
women with normal cytology without CIN disease was
33.2 years (range 18-53), and that of women with abnor-
mal cytology with CIN3 was 35.14 years (range 25-55).
This study followed the ethical guidelines of the Institu-
tional Review Board of the VU University Medical
Center.
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For methylation analysis, DNA was extracted from FFPE
specimens by proteinase K digestion and purified using
the High Pure PCR Template Preparation Kit (Roche
Diagnostics, Almere, The Netherlands) following the
manufacturer's recommendations. Genomic DNA from
cell lines and frozen specimens was extracted by protei-
nase K digestion followed by standard phenol-chloroform
extraction as described previously [35].
For hsa-miR-124 expression analysis, frozen specimens
of normal cervix, CIN2/3 lesions, SCCs, and AdCAs were
first enriched for epithelial cells by means of laser capture
microdissection using a Leica ASLMD microscope
(Leica, Heidelberg, Germany) as described before [36].
Subsequently, total RNA was isolated from these samples
and cell lines using TRIzol reagent (Life Technologies,
Breda, The Netherlands), according to the manufacturer's
instructions.
HPV typing of clinical specimens was performed using
the general primer GP5+/6+ PCR, followed by reverse
line blot, as described previously [37,38] (Additional file
1).
DNA modification and quantitative methylation-specific 
PCR (qMSP) analysis
The DNA methylation status of the CpG-island contain-
ing promoter regions associated with the three genomic
loci encoding hsa-miR-124 (hsa-miR-124-1, hsa-miR-
124-2 and hsa-miR-124-3) was determined by qMSP
analysis on sodium bisulfite-treated genomic DNA from
cell lines, tissue specimens and scrapings. In brief,
genomic DNA was modified using the EZ DNA Methyla-
tion kit (Zymo Research, Orange, CA, USA), which
induces chemical conversion of unmethylated cytosines
into uracils, whereas methylated cytosines are protected
from this conversion. Specific primers were designed to
amplify the methylated DNA sequence of all 3 promoter
regions. Amplicons (hsa-miR-124-1: -191 to -97; hsa-
miR-124-2: -301 to -163; hsa-miR-124-3: -106 to -11 rela-
tive to the transcription start site, respectively) were
detected and quantified using TaqMan probes (Table 1).
In addition, the modified, unmethylated sequence of the
housekeeping gene β-actin (ACTB) was amplified as a
reference [39]. qMSP reactions were carried out in a 12 μl
reaction volume containing 50 ng of bisulfite-treated
DNA, 417 nM of each primer, 208 nM probe and 1×
QuantiTect Probe PCR Kit master mix (Qiagen, West-
burg, Leusden, The Netherlands) using the ABI 7500 Fast
Real-Time PCR System (Applied Biosystems, Nieu-
werkerk a/d IJssel, The Netherlands).
All PCR experiments were performed in duplicate
(delta Ct ≤1.5 between replicates) and mean values were
used for calculations. Methylation values of the 3 target
regions were normalised to the reference gene ACTB
using the comparative Ct method (2-ΔCT) [40]. All methy-
lation negative samples in our study had a Ct for ACTB
below 32, indicating sufficient DNA quality and thereby
excluding false negative results. To ensure the detection
of distinguishable increases in methylation level in
(pre)malignant cervical lesions over normal cervical con-
trols, we used the 99% confidence interval of the methyla-
tion levels obtained in normal cervical controls as cut-off
value. Samples above this threshold were considered pos-
itive for methylation. For tissue specimens and scrapings
separate cut-off values were determined using the appro-
priate normal controls.
Retroviral transduction
Retroviral hsa-miR-124 or empty vector (ctrl) constructs
previously described by Voorhoeve et al [41] were trans-
fected into the Phoenix A retrovirus producer cell line
and supernatants containing the replication-deficient
hsa-miR-124-expressing retrovirus or empty vector ret-
rovirus were harvested 48 hours post-transfection. For
the transduction experiments, SiHa and CaSki cells were
incubated for 16 hours at 37°C with filtered viral superna-
tants supplemented with polybrene (15 μg/ml). SiHa/
CaSki_miR-124 cells or SiHa/CaSki_ctrl cells were
selected by continuous culturing of the transduced cells
in the presence of blasticidin (3 μg/ml).
Quantitative Reverse Transcription-PCR (qRT-PCR)
Expression of hsa-miR-124 was measured using TaqMan
microRNA assays following the manufacturer's instruc-
tions (00046 and 001182; Applied Biosystems) on the ABI
7500 Fast Real-Time PCR System (Applied Biosystems).
The small nucleolar RNA transcript RNU43 was included
as internal reference for hsa-miR-124 expression (001095;
Applied Biosystems). Hsa-miR-124 expression values
were normalised to the reference again by using the com-
parative Ct method as described above.
Intron-flanking primers for IGFBP7, a potential target
gene of hsa-miR-124, were selected using Primer Express
3.0 (Applied Biosystems) (Table 1). Total RNA was
reverse transcribed using the specific reverse primer and
the resulting cDNA was used for real-time PCR. cDNA
corresponding to 25 ng of total RNA was amplified in a
total reaction volume of 25 μl containing 12.5 μl 2x Sybr
Green master mix (Perkin Elmer/Applied Biosystems)
and 0.5 μM primers. The house keeping gene U1 small
nuclear ribonucleoprotein specific A protein (snRNP
U1A) was included as internal reference (Table 1).
Expression values of IGFBP7 were normalized to this ref-
erence by using the comparative Ct method as described
above.
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Cell proliferation was measured using a colorimetric
(MTT-tetrazolium) assay (ICN Biomedicals Inc, OH,
USA). In this assay the amount of dye conversion, as mea-
sured by the optical density at a wavelength of 540 nm, is
directly related to the number of viable cells in each well.
In brief, 5000 cells (CaSki) or 10000 cells (SiHa) were
seeded in triplicate in 96-well plates and assayed for MTT
conversion at day 0, day 1, day 2 and day 5 for CaSki and
day 0, day 2, day 3 and day 6 for SiHa. The proliferation
rate was determined by subtracting the measurement of
day 0 from all other time points.
Cellular migration in vitro was determined using a so-
called wound-healing assay. Cells were grown to conflu-
ency in 24-well plates and a single linear scratch was
made in duplicate for all conditions using a sterile tip,
resulting in a cell-free zone. Photographs of the scratch
were taken immediately post-scratching and following 24
hours of incubation at 37°C. After 48 hours cells were
fixed with methanol and stained with crystal violet solu-
tion.
Statistical analysis
Proliferation rates between hsa-miR-124-expressing cells
and control cells were compared using the Student's t
test. The frequency of methylation between normal and
low-grade (CIN1) lesions on one hand and high-grade
(CIN3) lesions and SCCs on the other hand were com-
pared using χ2-testing. The difference in hsa-miR-124
expression between normal cervical epithelium and
CIN2/3 lesions and carcinomas was compared using the
Wilcoxon rank test. Linear (Pearson) correlation was
determined between hsa-miR-124 methylation levels and
hsa-miR-124 expression.
Results
Methylation of hsa-miR-124 during hrHPV-mediated 
transformation in vitro
To determine whether hsa-miR-124 may be silenced due
to promoter hypermethylation in cervical cancer, we
assessed DNA methylation at the 3 promoter regions of
hsa-miR-124 (hsa-miR-124-1 located at 8p23.1; hsa-miR-
124-2 located at 8q12.3; and hsa-miR-124-3 located at
20q13.33) in cervical cancer cell lines using qMSP analy-
sis. Methylation of all 3 promoter regions of hsa-miR-124
was observed in SiHa cells as well as in another cervical
cancer cell line, CaSki. A third cervical cancer cell line,
HeLa, showed lower levels of methylation for all 3 regions
and especially methylation levels of hsa-miR-124-1 were
extremely low compared to SiHa and CaSki. Primary
keratinocytes isolated from 3 independent donors, on the
other hand, were completely unmethylated at all 3
regions (Figure 1A-C). Treatment of the cervical cancer
cell line SiHa with the demethylating agent DAC resulted
in > 50% decrease of methylation levels at all 3 regions
and increased expression of hsa-miR-124 compared to
untreated and mock-treated SiHa cells (PBS) (Figure 1D
and 1E).
To investigate at which stage during hrHPV-mediated
transformation hsa-miR-124 becomes methylated we
subsequently performed qMSP analysis for all 3 regions
on early and late passages of HPV16 (FK16A and FK16B)
Table 1: Sequences of qMSP and qRT-PCR primers used in this study
Gene Primers(5'-3') Size (bp) Annealing (°C)
hsa-miR-124-1 F: CGGCGGGGAGGATGTT 58.9
R: ATAAAAAACGACGCGTATACGTACG 94 59.4
P: CGGCGTTTTTTATTTTT-Xsprobe 70.0
hsa-miR-124-2 F: GGGTAATTAATTTGGATTTACGTCGTTAT 59.9
R: CGTAAAAATATAAACGATACGTATACCTACGT 138 58.8
P: TTTACAACACACGCCTAAA -Xsprobe 69.0
hsa-miR-124-3 F: ACGCGGCGAAGACGTTT 59.0
R: CGAACGACGAACGTCGAAA 95 59.4
P: AAAATCCTCGCCCGAAAAACGCGA 70.4
IGFBP7 F: CCCAGGTGTACTTGAGCTGTGA 89 58.9
R: TGAACTCCATAGTGACCCCTTTTT 58.9
snRNP U1A F: TCCTCACCAACCTGCCAGA 71 58.8
R: TGAAGCCAGGGAACTGATTGA 59.3
F: forward; R: reverse; P: probe; Xsprobe: minor groove binder probe
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Page 5 of 14and HPV18 (FK18A and FK18B) immortalised keratino-
cyte cell lines. Whereas early passages (range: p23-p43) of
all 4 cell lines showed little to no methylation, increased
methylation of hsa-miR-124-1 and hsa-miR-124-2 was
observed in late passages (range: p70-p96) (Figure 2A and
2B). For hsa-miR-124-1 an increase in methylation levels
was observed in late passages of FK16B and FK18A cells.
However, the levels of methylation were still very low
compared to those observed in SiHa and CaSki cells (Fig-
ure 1A). For hsa-miR-124-2, late passages of FK18A and
FK18B cells showed increased methylation, of which the
methylation level in late passage FK18B cells was compa-
rable to that observed in SiHa cells (Figure 1B). Methyla-
tion of the hsa-miR-124-3 region was not detected in any
of the HPV-immortalised keratinocytes (data not shown).
The increase in hsa-miR-124-1 methylation in late pas-
sage FK16B cells, though being quite low compared to
SiHa and CaSki cells, was associated with reduced hsa-
miR-124 expression compared to its corresponding ear-
lier passage (Figure 2C). Similarly, in late passage FK18B
cells, showing methylation levels for hsa-miR-124-2 com-
parable to SiHa cells, lower hsa-miR-124 expression was
found compared to its earlier passage. Together, these
results further support a (direct) correlation between
Figure 1 Hsa-miR-124 methylation in primary keratinocytes (EK cells) and cervical cancer cell lines SiHa, CaSki and HeLa. A. hsa-miR-124-1 
methylation, B. hsa-miR-124-2 methylation, C. hsa-miR-124-3 methylation. Whereas in primary keratinocytes no methylation was detectable, all cer-
vical cancer cell lines were positive for methylation of hsa-miR-124-1, hsa-miR-124-2 and hsa-miR-124-3. D. In SiHa cells treated with 5000 nM DAC, 
methylation levels of hsa-miR-124-1 (black), hsa-miR-124-2 (white) and hsa-miR-124-3 (grey) were reduced by more than 50%. Methylation levels of 
all regions in untreated cells were set to 100%. E. Whereas in untreated and mock (PBS) treated SiHa cells no hsa-miR-124 expression was detectable, 
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Page 6 of 14methylation and expression of hsa-miR-124. Methyla-
tion-mediated silencing of hsa-miR-124 appears to occur
during HPV-induced carcinogenesis at the post-immor-
talisation stage and is not directly related to the presence
of hrHPV.
Tumour suppressive activities of hsa-miR-124 in cervical 
cancer cell lines
The fact that methylation of hsa-miR-124 is consistently
found in cervical cancer cell lines and appears to be asso-
ciated with gene silencing, suggests that hsa-miR-124
may possess tumour suppressive traits in cervical cancer.
To test this hypothesis, we stably transduced SiHa and
CaSki cells with a retroviral hsa-miR-124-containing vec-
tor (SiHa_miR-124 and CaSki_miR-124, respectively) and
an empty vector (SiHa_ctrl and CaSki_ctrl, respectively).
Ectopic expression of hsa-miR-124 was confirmed by
qRT-PCR (Figure 3A). To determine the effects of ectopic
hsa-miR-124 expression on proliferation we measured
cell viability using the MTT assay. The proliferation rate
was significantly lower in SiHa_miR-124 compared to
SiHa_ctrl cells and parental SiHa cells (Figure 3B; p <
0.01). In CaSki cells effects were less pronounced, but
proliferation rates were still significantly lower in
CaSki_miR-124 compared to both CaSki_ctrl and CaSki
parental cells (Figure 3C; p < 0.05). The somewhat
reduced effect observed in CaSki_miR-124 cells com-
pared to SiHa_miR-124 cells is likely correlated to the lev-
els of hsa-miR-124 overexpression (Figure 3A).
To measure effects of hsa-miR-124 expression on the
migratory capacity of SiHa cells we performed a wound-
healing assay. Duplicate experiments consistently showed
decreased migratory capacity of SiHa_miR-124 com-
pared to SiHa_ctrl cells and parental SiHa cells at 24 and
48 hours (Figure 3D).
In conclusion, these results suggest that ectopic expres-
sion of hsa-miR-124 in cervical cancer cells has tumour
suppressive effects.
IGFBP7 is a potential target of hsa-miR-124 in a subset of 
cervical cancers
To identify potential hsa-miR-124 target genes in cervical
cancer we used data from a recent study by Baek et al, in
which the impact of hsa-miR-124 expression in HeLa
cells on mRNA and protein output was determined [17].
Interestingly, they found that for targets undergoing
robust (>1.5 fold) repression, the major mechanism of
repression was mRNA destabilisation. Therefore we com-
pared their proteomics data on HeLa cells ectopically
expressing hsa-miR-124 to our own dataset of genome-
wide mRNA expression in cervical SCCs, all of which
showed hsa-miR-124 methylation by qMSP analysis (data
not shown) [36]. This comparison highlighted 1 gene
containing an hsa-miR-124 target site, namely IGFBP7,
that showed 3.7 fold protein downregulation in
HeLa_miR124 cells and a significant (false discovery rate
(FDR) = 0.036) mRNA upregulation in cervical SCCs dis-
playing hsa-miR-124 methylation.
Quantitative RT-PCR was performed for IGFBP7 in
early and late passages of FK16B and FK18B cells as well
as SiHa and CaSki cells with and without ectopic hsa-
miR-124 expression, to determine the effects of hsa-miR-
124 on the mRNA level of IGFBP7. Interestingly, late pas-
sages of FK16B and FK18B cells, which were shown to
Figure 2 Hsa-miR-124 methylation and expression in early and 
late passages of HPV16 (FK16A/FK16B) and 18 (FK18A/FK18B) im-
mortalised keratinocytes. A. hsa-miR-124-1, B. hsa-miR-124-2. Both 
hsa-miR124-1 and hsa-miR-124-2 showed little to no methylation in 
early passages and increasing levels of methylation in later passages of 
HPV16 and HPV18 immortalised cells.  Note the difference in scales of 
Figure 2A and 2B. Levels of hsa-miR-124-1 methylation in HPV-immor-
talised keratinocytes are very low compared to the levels seen in cervi-
cal cancer cell lines (Figure 1A). No methylation of hsa-miR-124-3 was 
found in HPV-immortalised keratinocytes. C. Late passages of FK16B 
and FK18B cells showed reduced expression of hsa-miR-124 compared 
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Figure 3 Ectopic expression of hsa-miR-124 in SiHa and CaSki cells. A. Whereas parental cell lines and empty vector control cells (SiHa_ctrl and 
CaSki_ctrl) showed no detectable expression of hsa-miR-124, cells transduced with hsa-miR-124 (SiHa_miR-124 and CaSki_miR-124) expressed hsa-
miR-124. Ectopic hsa-miR-124 expression resulted in decreased proliferation rates of B. SiHa_miR-124 (red) and C. CaSki_miR-124 (red) compared to 
parental (black) and empty vector control cells (grey). In D. results of wound-healing assays in SiHa_miR-124, SiHa_ctrl and SiHa cells are shown, indi-
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Page 8 of 14have increased levels of hsa-miR-124-1 and hsa-miR-124-
2 methylation and decreased levels of hsa-miR-124
expression (Figure 2), showed increased levels of IGFBP7
expression compared to their corresponding early pas-
sages (Figure 4A). In CaSki cells ectopic hsa-miR-124
expression resulted in reduction of IGFBP7 expression of
more than 50% compared to the empty vector control
cells and parental cells, however, no effect was observed
in SiHa_miR-124 cells. As a control, SLC25A36, a gene
without any hsa-miR-124 target sites, was included in this
analysis and showed similar expression levels in cells with
and without ectopic hsa-miR-124 expression (Figure 4B).
These results indicate that IGFBP7 may be a target of
hsa-miR-124 in part of the cervical carcinomas.
hsa-miR-124 methylation and silencing is frequent in 
cervical (pre)malignant lesions
Since methylation of hsa-miR-124 becomes detectable in
late passages of HPV-immortalised keratinocytes mim-
icking premalignant cervical disease [33], these regions
may provide markers for the detection of cervical cancer
and its high-grade precursor lesions. We therefore deter-
mined the methylation levels of all promoter regions in
18 normal cervical specimens, 36 CIN1 lesions, 41 CIN3
lesions, 29 SCCs and 15 AdCAs (Figure 5A-C). Using a
cut off value based on the 99% confidence interval of the
mean value measured in the normal specimens, only 1
normal sample (5.6%) scored positive for hsa-miR-124-3
methylation, whereas no normal samples scored positive
for hsa-miR-124-1 and hsa-miR-124-2 methylation. For
hsa-miR-124-1 and hsa-miR-124-2, respectively, the per-
centages of methylation positivity increased from 27.8%
and 5.6% in CIN1, to 46.3% and 19.5% in CIN3, to 86.2%
and 82.8% in SCCs. In addition, high percentages of
methylation positivity for hsa-miR-124-1 and hsa-miR-
124-2 were found in AdCAs as well (93.3% and 80%
respectively). In concordance with the fact that in vitro
hsa-miR-124-3 was only methylated in cervical cancer
cell lines and not in HPV-immortalised precursor cell
lines, the frequency of hsa-miR-124-3 methylation was
low in CIN1 (11.1%) and CIN3 (9.8%) lesions, but
increased to 72.4% and 73.3% in SCCs and AdCAs,
respectively (Table 2).
A combined scoring system for hsa-miR-124-1 and/or
hsa-miR-124-2 methylation resulted in 0% positivity in
normal cervix, 30.6% in CIN1 lesions, 58.5% in CIN3
lesions and 93.1% in SCCs (Table 2). The difference in
methylation frequency between normal samples and low-
grade lesions (CIN1) on one hand and high-grade lesions
(CIN3) and SCCs on the other hand was highly signifi-
cant (p < 0.001). Addition of hsa-miR-124-3 methylation
resulted in the detection of one extra AdCA as well as one
extra normal specimen.
To determine whether hsa-miR-124 methylation also
resulted in silencing of hsa-miR-124 expression in cervi-
cal lesions, we measured the expression of hsa-miR-124
in a panel of frozen specimens of normal cervical
squamous epithelium (n = 5), CIN2/3 (n = 7), cervical
SCCs (n = 9) and AdCAs (n = 5). To eliminate the possi-
bility of confounding results due to stromal expression,
all samples were microdissected. The average expression
of hsa-miR-124 in CIN2/3 lesions and cervical carcino-
mas compared to normal cervical epithelium was 4.4 fold
decreased (p = 0.001). In addition, we determined the
correlation between hsa-miR-124 expression and methy-
lation levels for the 3 regions in CIN2/3 lesions and carci-
nomas (Figure 6). Methylation levels of hsa-miR-124-1
and hsa-miR-124-2 were significantly negatively corre-
lated with hsa-miR-124 expression levels (R = -0.451, p =
Figure 4 IGFBP7 and SLC25A36 expression in HPV-immortalised 
cells and cervical cancer cells transduced with hsa-miR-124. A. Ex-
pression levels of IGFBP7, a potential target gene of hsa-miR-124, were 
increased in late passages of FK16B and FK18B cells, also showing in-
creased methylation of hsa-miR-124, compared to their corresponding 
early passages. B. Effects of ectopic hsa-miR-124 expression on mRNA 
expression of IGFBP7 (grey bars) in SiHa and CaSki cells. Expression of 
SLC25A36 (white bars), a gene without an hsa-miR-124 target site, was 
also determined as a control. Expression in CaSki_ctrl and SiHa_ctrl was 
set to 100%, respectively. Results from 3 independent experiments 
showed that IGFBP7 expression was decreased in CaSki_miR-124 but 
not in SiHa_miR-124 cells compared to their parental and empty vec-
tor control cell lines. Expression of SLC25A36 was similar in cells with 
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Figure 5 Hsa-miR-124 methylation levels in cervical specimens. Dotplots showing the levels of methylation for A. hsa-miR-124-1, B. hsa-miR-124-
2 and C. hsa-miR-124-3 in normal cervical specimens, CIN1 lesions, CIN3 lesions, SCCs and AdCAs. Methylation levels in cervical scrapes of women with 
normal cytology without underlying CIN and women with abnormal cytology with underlying CIN3 lesions are shown in D. for hsa-miR-124-1, E. for 
























































Table 2: Frequencies of hsa-miR-124 methylation detected by qMSP analysis
methylation positivity (%) Combined (and/or) methylation positivity (%)
hsa-miR-124-1 hsa-miR-124-2 hsa-miR-124-3 hsa-miR-124-1/-2/-3 hsa-miR-124-1/-2 hsa-miR-124-1/-3 hsa-miR-124-2/-3
Normal (n = 18) 0.0 0.0 5.6 5.6 0.0 5.6 5.6
CIN1 (n = 36) 27.8 5.6 11.1 30.6 30.6 27.8 13.9
CIN3 (n = 41) 46.3 19.5 9.8 58.5 58.5 48.8 26.8
SCC (n = 29) 86.2 82.8 72.4 93.1 93.1 89.7 86.2
AdCA (n = 15) 93.3 80.0 73.3 100.0 93.3 100.0 93.3
normal cytology without CIN (n = 22) 4.5 0.0 4.5 9.1 4.5 9.1 4.5
abnormal cytology with CIN3 (n = 21) 47.6 47.6 23.8 71.4 71.4 57.1 47.6
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Page 11 of 140.04 and R = -0.631, p = 0.002, respectively), whereas for
hsa-miR-124-3 no significant correlation was found (R = -
0.360, p = 0.109).
Hsa-miR-124 methylation in cervical scrapes is predictive of 
underlying lesions
To be considered as a candidate disease marker that
potentially could be of value for the detection of high-
grade CIN and carcinoma in cervical screening, methyla-
tion of hsa-miR-124 should be detectable in cervical
scrapes containing few abnormal cells in a background of
normal cells. As a proof of principle we analysed the
methylation levels of all 3 loci in 22 hrHPV-positive cyto-
logically normal cervical scrapes of women without evi-
dence of CIN disease in the subsequent 5 years and 21
hrHPV-positive cytologically abnormal scrapes of
women with CIN3, diagnosed within 18 months of fol-
low-up (Figure 5D-F). Using the same analysis method as
described above, we found methylation of hsa-miR-124-1
and/or hsa-miR-124-2 in 4.5% (1/22) of the women with-
out disease versus 71.4% (15/21) of women with CIN3.
Methylation analysis of hsa-miR-124-3 had no additive
value in this sample series (Table 2).
Collectively, these results show that methylation analy-
sis of hsa-miR-124-1 and hsa-miR-124-2 provides an
attractive candidate marker for the triage of hrHPV-posi-
tive women.
Discussion
In this study we showed that epigenetic silencing of hsa-
miR-124 is functionally involved in cervical carcinogene-
sis and may provide a valuable marker for risk stratifica-
tion of hrHPV-positive women. Using qMSP analysis, we
found methylation of hsa-miR-124-1 and/or hsa-miR-
124-2 in none of the normal tissues, 58.5% of CIN3
lesions, 93.1% of SCCs and 93.3% of AdCAs. Increased
methylation levels of hsa-miR-124-1 and hsa-miR-124-2
in cervical tissue specimens were significantly correlated
with lower hsa-miR-124 expression levels. Analysis of
cervical scrapes showed that only 4.5% of hrHPV-positive
scrapes without CIN disease in follow-up was positive
compared to 71.4% of hrHPV-positive scrapes with CIN3
in follow-up. To the best of our knowledge this study pro-
vides the first evidence of DNA methylation-based silenc-
ing of a miRNA in cervical cancer.
Methylation of hsa-miR-124 was found in cervical can-
cer cell lines SiHa, CaSki and HeLa as well as in late pas-
sages of HPV16/18 immortalised keratinocytes,
reminiscent of high grade cervical precursor lesions, but
not in normal primary keratinocytes. The fact that meth-
ylation of hsa-miR-124 and concomitant reduced hsa-
Figure 6 Correlation between hsa-miR-124 methylation and ex-
pression in cervical tissue specimens. The overall correlation be-
tween A. hsa-miR-124-1, B. hsa-miR-124-2 and C. hsa-miR-124-3 
methylation levels and hsa-miR-124 expression in CIN2/3 lesions, SCCs 
and AdCAs is shown.
A. Pearson correlation R=-0.451 (p=0.04)
B.
Pearson correlation R=-0. 631 
(p=0.002)
Pearson correlation R= 0 360C. - .
(p=0.109)
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Page 12 of 14miR-124 expression was found in late passages of HPV-
immortalised keratinocytes but not in early passages,
indicates that this event takes place post-immortalisation
and is not directly related to the presence of hrHPV. Ecto-
pic expression of hsa-miR-124 decreased the proliferation
rate of both SiHa and CaSki cells and also inhibited the
migratory capacity of SiHa cells. Effects on the migratory
capacity of CaSki cells were difficult to ascertain due to
the specific growth characteristics of this cell line. Con-
sistent with our findings, both Agirre et al and Furuta et
al observed inhibitory effects on cellular growth upon
reintroduction of hsa-miR-124 expression in acute lym-
phoblastic leukaemia (ALL)-derived cells and hepatocel-
lular carcinoma cell lines [26,32].
One of the previously identified targets mediating the
tumour suppressive function of hsa-miR-124 is CDK6, via
CDK6 mediated phosphorylation and subsequent inacti-
vation of the tumour suppressor pRb [29,32]. However, in
cervical cancer the virally encoded oncoprotein E7 is
thought to bind and inactivate pRb, suggesting hsa-miR-
124 may (partly) function via other targets in this type of
cancer. Using data from a recent study by Baek et al, we
identified IGFBP7 as a promising target gene in cervical
cancer [17]. IGFBP7 mRNA levels were increased in late
passages of FK16B and FK18B cells compared to their
corresponding early passages, which also showed
increased levels of hsa-miR-124-1 and hsa-miR-124-2
methylation and decreased levels of hsa-miR-124 expres-
sion. In addition, IGFBP7 showed decreased mRNA
expression in CaSki cells ectopically expressing hsa-miR-
124 compared to empty vector control cells and parental
cells. No effect was seen in SiHa_miR-124 cells, however.
These results indicate that IGFBP7 may be a potential
target of hsa-miR-124 in part of the cervical cancers, but
other targets may be relevant for the tumour suppressive
function of hsa-miR-124 in cervical cancer as well.
IGFBP7 is part of the insulin-like growth factor (IGF)
axis, which has been implicated in cervical cancer before.
It was shown that the IGF-axis may influence the persis-
tence of hrHPV infections and that abnormally balanced
co-expression of IGFBP family members is associated
with gynaecological malignancy [42,43]. IGFBP7 is the
only member of the IFGBP family that binds insulin
instead of IGF and is relatively unknown compared to its
family members. On one hand IGFBP7 has recently been
described as a tumour suppressor gene in colorectal can-
cer and was shown to induce senescence in cells harbour-
ing oncogenic BRAF [44-46], whereas on the other hand
IGFBP7 was shown to have oncogenic properties in
gliomas [47]. Further functional studies are needed to
investigate whether the tumour suppressive function of
hsa-miR-124 in cervical cancer may in part be mediated
via IGFBP7.
Hsa-miR-124 was originally described as a brain-spe-
cific miRNA, involved in neuronal differentiation. Lujam-
bio et al were the first to show methylation-mediated
silencing of hsa-miR-124 in different human cancer
types, reaching the highest frequency in colorectal cancer
(75%) [29]. In acute lymphoblastic leukaemia (ALL)
methylation of hsa-miR-124 was shown to negatively
affect clinical outcome [30,32]. In ALL hsa-miR-124-1
showed the highest frequency of methylation as was also
found for cervical cancer in our study. Interestingly, in
gastric cancer and hepatocellular carcinoma, hsa-miR-
124-3 showed the highest frequency of methylation
[25,26], whereas in ALL and cervical cancer hsa-miR-
124-3 showed the lowest frequencies of methylation posi-
tivity. This may indicate that hsa-miR-124-3 methylation
is tissue or tumour type dependent. The fact that hsa-
miR-124-3 methylation was infrequent in cervical pre-
cursor lesions and HPV-immortalised keratinocyte cell
lines supports the notion that at least in cervical carcino-
genesis hsa- miR-124-3 methylation is a rather late event.
Overall, the methylation positivity rates for hsa-miR-124
found in our study rank among the highest currently
reported, although the use of different assays and meth-
ods, including non-quantitative MSP and combined
bisulfite restriction analysis, makes a direct comparison
difficult. Importantly, hsa-miR-124 methylation in cervi-
cal cancer was histotype-independent and could already
be detected in CIN3 lesions and scrapes of women with
underlying CIN3, underlining its potential value for cer-
vical cancer screening.
Conclusions
This study shows that methylation of hsa-miR-124 is a
frequent and functionally relevant event in cervical car-
cinogenesis. The high positivity rates in CIN3 lesions and
carcinomas as well as in scrapes with underlying CIN3
lesions combined with the fact that hsa-miR-124 methy-
lation is not directly related to the presence of hrHPV,
indicate that hsa-miR-124 methylation may provide a
valuable marker for the triage of hrHPV-positive women.
Future studies in large population-based cohorts will
determine whether testing for hsa-miR-124 methylation
either or not in combination with other promising meth-
ylation markers such as CADM1 and MAL [13,14] can
improve future cervical screening strategies based on pri-
mary hrHPV testing.
Additional material
Additional file 1 HPV typing results of clinical specimens included in 
this study. In this additional table, for all clinical specimens included in this 
study, HPV typing results by general primer GP5+/6+ PCR and reverse line 
blot are given.
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